View in EDS PDF Full Text

Phase I Trial of 131I-GMIB-Anti-HER2-VHH1, a New Promising Candidate for HER2-Targeted Radionuclide Therapy in Breast Cancer Patients.

Saved in:
Bibliographic Details
Title: Phase I Trial of 131I-GMIB-Anti-HER2-VHH1, a New Promising Candidate for HER2-Targeted Radionuclide Therapy in Breast Cancer Patients.
Authors: D'Huyvetter M; Precirix NV/SA, Brussels, Belgium; marleen.keyaerts@vub.be.; In Vivo Cellular and Molecular Imaging Laboratory, Vrije Universiteit Brussel, Brussels, Belgium., Vos J; Precirix NV/SA, Brussels, Belgium., Caveliers V; In Vivo Cellular and Molecular Imaging Laboratory, Vrije Universiteit Brussel, Brussels, Belgium.; Nuclear Medicine Department, UZ Brussel, Brussels, Belgium., Vaneycken I; Nuclear Medicine Department, UZ Brussel, Brussels, Belgium., Heemskerk J; Nuclear Medicine Department, UZ Brussel, Brussels, Belgium., Duhoux FP; Medical Oncology Department, King Albert II Cancer Institute, Cliniques Universitaires Saint-Luc and Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, Brussels, Belgium., Fontaine C; Department of Medical Oncology, UZ Brussel, Brussels, Belgium., Vanhoeij M; Department of Oncological Surgery, UZ Brussel, Brussels, Belgium., Windhorst AD; Department of Radiology and Nuclear Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands., Aa FV; Department of Radiology and Nuclear Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands., Hendrikse NH; Department of Radiology and Nuclear Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands., Eersels JLE; Precirix NV/SA, Brussels, Belgium.; In Vivo Cellular and Molecular Imaging Laboratory, Vrije Universiteit Brussel, Brussels, Belgium., Everaert H; Nuclear Medicine Department, UZ Brussel, Brussels, Belgium., Gykiere P; Nuclear Medicine Department, UZ Brussel, Brussels, Belgium., Devoogdt N; Precirix NV/SA, Brussels, Belgium.; In Vivo Cellular and Molecular Imaging Laboratory, Vrije Universiteit Brussel, Brussels, Belgium., Raes G; Precirix NV/SA, Brussels, Belgium.; Lab of Cellular and Molecular Immunology, Vrije Universiteit Brussel, Brussels, Belgium; and.; Myeloid Cell Immunology Lab, VIB Center for Inflammation Research, Brussels, Belgium., Lahoutte T, Keyaerts M; In Vivo Cellular and Molecular Imaging Laboratory, Vrije Universiteit Brussel, Brussels, Belgium; marleen.keyaerts@vub.be.; Nuclear Medicine Department, UZ Brussel, Brussels, Belgium.
Source: Journal of nuclear medicine : official publication, Society of Nuclear Medicine [J Nucl Med] 2021 Aug 01; Vol. 62 (8), pp. 1097-1105. Date of Electronic Publication: 2020 Dec 04.
Publication Type: Journal Article; Clinical Trial, Phase I
Journal Info: Publisher: Society of Nuclear Medicine Country of Publication: United States NLM ID: 0217410 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1535-5667 (Electronic) Linking ISSN: 01615505 NLM ISO Abbreviation: J Nucl Med
Database: MEDLINE Ultimate
Description
ISSN:1535-5667
DOI:10.2967/jnumed.120.255679